362 related articles for article (PubMed ID: 21664472)
21. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
22. Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation.
Klyuchnikov E; Sputtek A; Slesarchuk O; Lioznov M; Stübig T; Bacher U; Amtsfeld G; Merle E; Reckhaus ML; Fehse B; Wolschke C; Adjallé R; Ayuk F; Zander A; Kröger N
Biol Blood Marrow Transplant; 2011 Mar; 17(3):374-83. PubMed ID: 20637880
[TBL] [Abstract][Full Text] [Related]
23. Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
Rettinger E; Kreyenberg H; Merker M; Kuçi S; Willasch A; Bug G; Ullrich E; Wels WS; Bonig H; Klingebiel T; Bader P
Cytotherapy; 2014 Jun; 16(6):835-44. PubMed ID: 24582456
[TBL] [Abstract][Full Text] [Related]
24. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
[TBL] [Abstract][Full Text] [Related]
25. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
26. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
27. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
[TBL] [Abstract][Full Text] [Related]
28. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
29. CIK: a path to GVL without GVHD?
Martin PJ
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1571-2. PubMed ID: 21906574
[No Abstract] [Full Text] [Related]
30. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
Bethge WA; Hegenbart U; Stuart MJ; Storer BE; Maris MB; Flowers ME; Maloney DG; Chauncey T; Bruno B; Agura E; Forman SJ; Blume KG; Niederwieser D; Storb R; Sandmaier BM
Blood; 2004 Feb; 103(3):790-5. PubMed ID: 14525766
[TBL] [Abstract][Full Text] [Related]
31. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
32. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
33. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.
Bar M; Sandmaier BM; Inamoto Y; Bruno B; Hari P; Chauncey T; Martin PJ; Storb R; Maloney DG; Storer B; Flowers ME
Biol Blood Marrow Transplant; 2013 Jun; 19(6):949-57. PubMed ID: 23523892
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
[TBL] [Abstract][Full Text] [Related]
35. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A
Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328
[TBL] [Abstract][Full Text] [Related]
36. CIK as therapeutic agents against tumors.
Introna M
J Autoimmun; 2017 Dec; 85():32-44. PubMed ID: 28679475
[TBL] [Abstract][Full Text] [Related]
37. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
38. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
Rezvani AR; Storb RF
J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
[TBL] [Abstract][Full Text] [Related]
39. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
Bethge WA; Haegele M; Faul C; Lang P; Schumm M; Bornhauser M; Handgretinger R; Kanz L
Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
